Key facts
Financial results (Full-Year 2018)
Total revenue
$22.09bn
↓ 2% at CER
Core earnings per share
$3.46
↓ 19% at CER
Full-Year 2018 Results
14 February 2019
SEC filings
SEC filings are those documents that we are required to file by virtue of our listing on the New York Stock Exchange. They contain mainly financial information.
These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:
Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
Our pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
150
projects in our pipeline
8
new molecular entities in our late-stage pipeline
1
new molecular entity approval in last quarter
Contact us
Investor enquiries
Main Contacts
-
Annual reports
Our Annual Report provides a wide range of information about our global business.
-
Our Pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development
